Advertisement

Topics

Artielle ImmunoTherapeutics Company Profile

08:08 EDT 23rd September 2018 | BioPortfolio


News Articles [66 Associated News Articles listed on BioPortfolio]

Boehringer and OSE Immunotherapeutics to develop new cancer drug

Boehringer Ingelheim has formed an alliance with OSE Immunotherapeutics to develop a SIRP-alpha antagonist compound to treat advanced solid tumours....Read More... The post Boehringer and OSE Immunoth...

OSE Immunotherapeutics And Servier Join Forces In Auto-Immune Field

French groups OSE Immunotherapeutics and Servier have inked a pact to develop and commercialize the newly formed biotech's interleukin-7 antagonist...   

Boehringer, OSE Immunotherapeutics sign $1.4bn immuno-oncology deal

Boehringer Ingelheim has entered into an exclusive worldwide collaboration and license agreement with OSE Immunotherapeutics for the development of a new checkpoint inhibitor to treat solid tumors.

OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi

Funding through the Eurostars European Programme, led in France by Bpifrance Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE) today announces that the Compan...

BI acquires exclusive worldwide license to OSE Immunotherapeutics' mAb OSE172

In a deal valued at over €1.1bn ($1.39bn) OSE Immunotherapeutics SA exclusively licensed Boehringer Ingelheim GMBH worldwide rights to monoclonal antibody OSE172 (Effi-dem).

Boehringer Ingelheim and OSE Immunotherapeutics Ink $1.4B Deal

Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.

ProBioGen and Pionyr Immunotherapeutics initiate second collaboration

ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, andPionyr Immunotherapeutics, an immuno-oncology company which develops next generation antibody-based th...

OSE Immunotherapeutics Announces Participation At The H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE), today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Science...

Drugs and Medications [0 Results]

None

PubMed Articles [98 Associated PubMed Articles listed on BioPortfolio]

Recent developments with immunotherapy for hepatocellular carcinoma.

Immunotherapy is on the way to become the new standard of care for advanced hepatocellular carcinoma (HCC) worldwide. With higher rates of objective responses, and overall less side effects compared t...

Human Vaccines & Immunotherapeutics: News.

Human Vaccines & Immunotherapeutics: News.

Human Vaccines & Immunotherapeutics: News.

Human Vaccines & Immunotherapeutics: News.

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

The investigators propose to evaluate cabozantinib in combination with durvalumab in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malig...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [22 Associated Companies listed on BioPortfolio]

Artielle ImmunoTherapeutics

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...

OSE Immunotherapeutics

Avant Immunotherapeutics

AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a...

More Information about "Artielle ImmunoTherapeutics" on BioPortfolio

We have published hundreds of Artielle ImmunoTherapeutics news stories on BioPortfolio along with dozens of Artielle ImmunoTherapeutics Clinical Trials and PubMed Articles about Artielle ImmunoTherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Artielle ImmunoTherapeutics Companies in our database. You can also find out about relevant Artielle ImmunoTherapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record